CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation
Abstract
Anti-programmed death-ligand 1 (αPD-L1) immunotherapy is approved to treat bladder cancer (BC) but is effective in + antitumor T cells known to improve αPD-L1 efficacy. We hypothesized that the tumor microenvironment, including local immune cells in primary versus metastatic BC, differentially affects immunotherapy responses and that IL-2c effects could differ from, and thus complement αPD-L1.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 01, 2021
- Source ID
- 10.1136/jitc-2020-002051
Entities
People
- Alvaro S Padron
- Anand V R Kornepati
- Aravind Kancharla
- Chenghao Zhang
- Deyi Zhang
- Harshita B. Gupta
- Jose R Conejo-Garcia
- Karen Wheeler
- Myrna Garcia
- Neelam Mukherjee
- Niannian Ji
- Onur Boyman
- Robert S. Svatek
- Ryan M Reyes
- Tyler J Curiel
- Yilun Deng
Organizations
- Congressionally Directed Medical Research Programs
- National Cancer Institute
- William & Ella Owens Medical Research Foundation